Table 1 Clinical data and TMPRSS2:ERG gene fusion status from the 27 cases of prostate cancer and 5 cases of BPH with needle biopsy samples
From: Detection of tmprss2-erg and tmprss2-egr1 gene fusion in prostate cancer from a Chinese population
Case No. | age | pathology diagnosis | TPSA(ng/ml) | FPSA(ng/ml) | Gleason score | TMPRSS2:ERG gene fusion |
|---|---|---|---|---|---|---|
1 | 74 | PCa | 7.949 | 1.799 | 3+3 | neg |
2 | 75 | PCa | 17.163 | 1.212 | 4+4 | neg |
3 | 67 | Pca | 9.338 | 1.227 | 3+4 | T1/E5 and T3/E5 |
4 | 74 | PCa | 26.623 | 3.797 | 4+3 | neg |
5 | 64 | BPH | 18.865 | 3.256 | ND | neg |
6 | 83 | BPH | 16.518 | 0.781 | ND | neg |
7 | 70 | PCa | 11.612 | 1.246 | 3+4 | neg |
8 | 64 | BPH | 4.728 | 1.369 | ND | neg |
9 | 85 | BPH | 7.676 | 1.184 | ND | neg |
10 | 73 | BPH | 8.234 | 1.294 | ND | neg |
11 | 65 | PCa | 15.8 | ND | 3+3 | T1/E5 |
12 | 68 | PCa | 254.427 | 16.837 | 4+3 | T1/E5 |
13 | 67 | PCa | 17.696 | 1.461 | 3+3 | neg |
14 | 76 | Pca | 86.491 | 12.129 | 4+5 | neg |
15 | 59 | PCa | 8.372 | 0.883 | 3+3 | neg |
16 | 67 | PCa | 6.72 | 0.47 | 4+5 | neg |
17 | 69 | PCa | 18.67 | 0.89 | 3+4 | neg |
18 | 64 | PCa | 30.224 | 1.609 | 4+4 | T1/E5 |
19 | 53 | PCa | 56.975 | 7.59 | 4+4 | * |
20 | 71 | PCa | 19.21 | 5.046 | 4+5 | neg |
21 | 65 | PCa | 261.547 | 14.391 | 4+4 | neg |
22 | 83 | PCa | 184.176 | 20.899 | 4+4 | neg |
23 | 79 | PCa | 18.03 | 3.88 | 4+4 | neg |
24 | 70 | PCa | >1000 | ND | 4+5 | neg |
25 | 71 | PCa | 5.7 | ND | 4+5 | neg |
26 | 69 | PCa | 10.2 | ND | 3+5 | neg |
27 | 67 | PCa | 15.5 | ND | 4+4 | T1/E5 |
28 | 78 | PCa | >1000 | >30 | 3+5 | neg |
29 | 73 | PCa | 387.1 | >31 | 4+4 | T1/E5 |
30 | 66 | PCa | 88.7 | 8.87 | 3+4 | neg |
31 | ND | PCa | 19.5 | 3.4 | 3+3 | neg |
32 | 70 | PCa | 13.05 | ND | 5+4 | neg |